Relay Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $350.0K | $3.0M | $7.0M | $0 | $677.0K | $7.7M | $0 | $0 |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | — | — | — | — | — | — | — | — |
| SG&A Expense | $14.7M | $11.0M | $12.2M | $12.1M | $13.6M | $18.7M | $16.9M | $19.8M |
| Operating Income | $-90.8M | $-78.6M | $-60.6M | $-80.4M | $-76.8M | $-84.9M | $-85.0M | $-96.4M |
| Operating Margin | -25,949.7% | -2,619.7% | -866.3% | — | -11,351.1% | -1,105.2% | — | — |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-83.7M | $-73.3M | $-54.9M | $-74.1M | $-70.4M | $-77.1M | $-76.0M | $-88.1M |
| Net Margin | -23,916.3% | -2,443.0% | -784.3% | — | -10,395.1% | -1,003.6% | — | — |
| EPS (Basic) | $-0.41 | $-0.41 | $-0.31 | $-0.43 | $-0.41 | $-0.46 | $-0.42 | $-0.63 |
| EPS (Diluted) | $-0.41 | $-0.41 | $-0.31 | $-0.43 | $-0.41 | $-0.46 | $-0.42 | $-0.63 |
| Shares Outstanding (Basic) | 202.8M | 179.8M | 171.6M | 172.4M | 171.3M | 169.2M | 142.9M | 140.2M |
| Shares Outstanding (Diluted) | 202.8M | 179.8M | 171.6M | 172.4M | 171.3M | 169.2M | 142.9M | 140.2M |
| Dividends Per Share | — | — | — | — | — | — | — | — |